256 Newsroom — Uganda's Digital News Infrastructure
Health

As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill - Fierce Pharma

Published by FiercePharma By Angus Liu · 4 August 2026 at 21:38
Share
As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill - Fierce Pharma
Image · FiercePharma

What the report says

Long viewed as one of the biggest hype-to-disappointment stories in pharmaceutical history, the PCSK9 cholesterol drug class has struggled to live up to its commercial promise. Merck & Co. | The PCSK9 cholesterol drug class has long been viewed as one of the …

Read the full report at FiercePharma →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

More stories by this journalist

Other publications from this journalist — open any story without leaving the article page.

No other published stories from this publisher yet.

Related reporting

HTTC Crowns Uganda’s Finest Young Hospitality TalentNile Post 256 Newsroom Blend your way through smoothies to better health - Daily MonitorDaily Monitor NMS Pledges to Address Medicine Shortages, Delivery Delays in WakisoNile Post U. grad with stage 4 cancer heads to Washington to push for clinical trial access - KSL.comKSL.com 256 Newsroom Charcoal Grill serves up healthier dining - Daily MonitorDaily Monitor As antibiotic resistance grows, researchers turn to copper to fight infections - Phys.orgPhys.Org